High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment

Olsen, Lilian B.; Kjeldsen, Anette D.; Poulsen, Mikael K.; Kjeldsen, Jens; Fialla, Annette D.

Published in:
Orphanet Journal of Rare Diseases

DOI:
10.1186/s13023-020-01583-6

Publication date:
2020

Document version
Final published version

Document license
CC BY

Citation for published version (APA):
Olsen, L. B., Kjeldsen, A. D., Poulsen, M. K., Kjeldsen, J., & Fialla, A. D. (2020). High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment. Orphanet Journal of Rare Diseases, 15, [334]. https://doi.org/10.1186/s13023-020-01583-6
High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment

Lilian B. Olsen¹, Anette D. Kjeldsen¹,²,⁵, Mikael K. Poulsen¹,³,⁵, Jens Kjeldsen¹,⁴,⁵ and Annette D. Fialla¹,⁴,⁵*

Abstract

Background: This report addresses how patients with hereditary hemorrhagic telangiectasia (HHT) and high output cardiac failure (HOCF) due to hepatic vascular malformations, should be evaluated and could be treated. HHT is a genetic disorder, leading to vascular abnormalities with potentially serious clinical implications. In the liver, arteriovenous malformations occur in more than 70% of patients, but only about 8% present clinical symptoms such as HOCF with pulmonary hypertension and less commonly portal hypertension, biliary ischemia and hepatic encephalopathy.

Results: Three female patients with HHT type 2 and HOCF caused by severe arteriovenous malformations in the liver are presented in this case series. The patients were seen at the HHT-Centre at Odense University Hospital. Treatment with either orthotopic liver transplantation (one patient) or bevacizumab (two patients) was initiated. All patients experienced marked symptom relief and objective improvement. New York Heart Association—class were improved, ascites, peripheral edema and hence diuretic treatment was markedly reduced or discontinued in all three patients. Bevacizumab also resulted in notable effects on epistaxis and anemia.

Conclusion: Our findings substantiate the importance of identification of symptomatic arteriovenous malformations in the liver in patients with HHT. Bevacizumab may possibly, as suggested in this case series and supported by previous case studies, postpone the time to orthotopic liver transplantation or even make it unnecessary. Bevacizumab represents a promising new treatment option, which should be investigated further in clinical trials.

Keywords: Hereditary hemorrhagic telangiectasia, HHT, Vascular endothelial growth factor inhibitor, Bevacizumab, Hepatic, Right heart failure

Introduction

Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder, leading to vascular abnormalities with potentially serious clinical implications [1, 2]. It is an autosomal dominant disease with an estimated prevalence of 1:6,500 in Denmark [3]. It is commonly associated with multiple telangiectatic lesions at characteristic sites as the skin of the face and fingertips. HHT also manifests with telangiectatic lesions of the mucosa causing troublesome bleedings and potentially anemia. Finally, the patients may have visceral arteriovenous malformations (AVMs) in particular in the lungs, liver and central nervous system which can result in severe organ dysfunction and failure [4–7].
The HHT-diagnosis is established by the Curaçao criteria, which include spontaneous, recurrent epistaxis, telangiectasia in HHT-associated locations, visceral involvement and a family history [8].

The mutations involved in HHT most commonly affect genes coding for the Endoglin (ENG) and Activin receptor-like kinase 1 (ACVRL1) causing HHT type 1 and type 2, respectively [9, 10]. In rare cases, HHT is caused by mutations of the SMAD4 gene leading to a phenotype with concomitant juvenile polyposis [10, 11]. The common denominator of these mutations is that they result in loss of function of receptors belonging to the transforming growth factor beta (TGFβ) superfamily, which are present in endothelial cells, involved in angiogenesis and considered to be the cause of vascular dysfunction in HHT [12, 13].

The most common symptom in HHT is epistaxis occurring in more than 90% of patients [14, 15]. Another common clinical presentation is dyspnea and cyanosis due to AVMs in the lungs [16–18]. This is caused by shunting of blood from the pulmonary arterial bed to the pulmonary veins, bypassing the lung tissue.

Furthermore, telangiectatic lesions in the gastrointestinal (GI)-tract cause bleeding in up to 25% of patients and consequently cause anemia [19].

In the liver, AVMs occur in more than 70% of patients with HHT, but only about 8% present with clinical symptoms [4]. The AVMs form between the hepatic arteries and the liver veins causing high output cardiac failure (HOCF) with pulmonary hypertension, or between the hepatic arteries/or veins and the portal veins, causing portal hypertension, biliary ischemia and hepatic encephalopathy [20]. HOCF is characterized by high cardiac output secondary to an increased blood volume. In HHT-patients increased blood flow through liver AVMs, eventually lead to heart-failure. The patients may be diagnosed with HOCF while the underlying cause (the liver-AVMs) may be overlooked.

Treatment options for HHT with HOCF due to liver AVMs progressing to terminal HOCF have until now been limited. Thus, in terminal HOCF, orthotopic liver transplantation (OLT) has been the only treatment option [21–23].

Bevacizumab is a recombinant monoclonal antibody, which inhibits vascular endothelial growth factor (VEGF), a signal protein, which, among other functions, stimulates angiogenesis. It is commonly used in antineoplastic treatment [24–26].

In case reports and minor, non-randomized, studies on HHT patients with symptomatic liver AVMs, pharmacological treatment with bevacizumab has been shown to markedly reduce cardiac output and simultaneously reduce frequency and duration of epistaxis and GI-bleeding [27–31].

In this case series, three cases with HOCF caused by severe liver AVMs, treated with either OLT or bevacizumab are presented.

**Methods**

Three female patients two with confirmed and one with possible (VUS) HHT type 2 (Table 1), all treated in 2018 at the HHT-Centre at Odense University Hospital (OUH), are presented. The clinical evaluations and treatments were performed in collaboration

| Table 1 Baseline characteristics |
|---------------------------------|
| **Patient 1** | **Patient 2** | **Patient 3** |
|---|---|---|
| **Age (years)** | 65 | 80 | 66 |
| **Sex** | Female | Female | Female |
| **HHT-type** | 2 | 2 | VUS<sup>d</sup> |
| **Gene mutation** | ACVRL-1-c.1022A>T | ACVRL-1-c.1022A>T | ACVRL-1-c.941A>C<sup>b</sup> |
| **Height (cm)** | 161 | 163 | 160 |
| **Weight (kg)** | 53 | 60 | 47 |
| **Body Mass Index** | 21 | 23 | 18 |
| **PAVM** | Yes<sup>c</sup> | No | No |
| **GI-AVM** | Yes | Yes | No |
| **Epistaxis** | Yes, mild | Yes, mild | Yes, severe |

<sup>a</sup> Patients are related
<sup>b</sup> Not formerly known to be pathogenic
<sup>c</sup> 5 cm in diameter, embolized in 2009
<sup>d</sup> Having a variant of unknown significance in the ACVRL1 gene, means that we found a mutation but we do not know if it is a disease causing mutation or just a polymorphic variant. The conclusion for this patient is that the patient has HHT based on the clinical Curaçao criteria, but we cannot say for sure she has HHT type two ACVRL-1 activin receptor-like kinase 1, VUS variance of unknown significance, PAVM pulmonary arteriovenous malformation, GI-AVM gastrointestinal-AVM
between the Departments of Oto-Rhino-Laryngology, Cardiology and Medical Gastroenterology and Hepatology.

One patient was referred for OLT and two patients were treated with bevacizumab. Bevacizumab was administered during 6 series at a three-week interval, by intravenous infusion at a dose of 5 mg per kilogram of body weight followed by maintenance infusion every 3 months. The follow-up period for all three patients was 9 months.

A standard clinical evaluation is performed on patients referred to the national HHT-Centre under the suspicion of HHT. The work-up includes patient history, focusing on the Curaçao criteria as well as neurological symptoms, dyspnea and other cardiac symptoms. Blood samples are collected for blood count and genetic testing is performed to assess the disease causing mutation and if possible establish the disease subtype.

An index echocardiogram is performed in all HHT-patients at our center, regardless of symptoms. Contrast echocardiography is used as the first screening tool for pulmonary AVMs [32–35]. If this indicates pulmonary AVMs, a computed tomography (CT)-angiography is performed to identify AVMs. Secondly, if symptoms later on indicate congestive heart disease an echocardiogram is performed, at the time of symptoms. If the echocardiogram shows signs of pulmonary hypertension and/or right heart failure (right ventricular dilatation and/or reduced systolic function) a right heart catheterization is performed. Since congestive heart disease is a potential manifestation of hepatic AVMs, such findings always yield a follow-up CT angiography of the abdomen.

**Ethics**

Written informed consent was obtained from all patients, allowing their disease history to be published. The data are enclosed in the Danish HHT database, Danish Data Protection Agency (Jnr13/42,552).

---

**Results**

Patient 1 was a 65-year-old woman with HOCS symptoms and a Cardiac Index (CI) of 6.6 L/min/m², caused by liver AVMs (Tables 1, 5). During her first visit at the outpatient clinic, her symptoms were dyspnea, New York Heart Association (NYHA) class II, peripheral edema and atrial fibrillation (AF). She did not receive anticoagulation. She experienced epistaxis less than once a month (Tables 1, 2). An abdominal CT-scan revealed hepatomegaly, dilatation of the hepatic artery and vein and a magnetic resonance cholangiopancreatography showed signs of cholangiopathy, suggestive of hepato-biliary ischemia (Table 3). Furthermore, she had previously had a pulmonary AVM, which had successfully been treated with endovascular coil-embolization in 2009 (Table 1).

Patient 1 underwent OLT in July 2018 at the referral transplant centre in Copenhagen. Following transplantation her CI immediately decreased from 6.6 to 4.5 L/min/m². She suffered from post-surgical bleeding from a phrenic artery, inducing a drop in hemoglobin from 10.5 g/dL to 8.1 g/dL within 24 h. An abdominal ultrasound revealed an organized 1.3 L hematoma, posterior to the liver, which was drained by a small surgical procedure. Subjectively, dyspnea was reduced, which improved her NYHA-class from II to I, allowing for discontinuation of her diuretic treatment, as peripheral edemas were significantly reduced (Tables 2, 3, 5).

At 9 month follow-up, patient 1 was feeling better than before OLT, although she had experienced a long period of hospitalization due to cholangitis, secondary to surgical complications, which was treated with drainage. She suffered from anemia without signs of bleeding. The immunosuppressant treatment (mycophenolate mofetil and tacrolimus) was still well tolerated. She did not have any side effects from the immunosuppressant treatment.

Patient 2 was an 80-year-old woman with liver AVMs causing HOCS, with a CI of 5.4 L/min/m² (Tables 1, 5). She suffered from anemia caused by recurrent bleeding from gastrointestinal AVMs, dyspnea, NYHA class II and peripheral edema. Intermittently, she had required blood transfusions due to anemia (Tables 1, 2, 3, 4). OLT

| Table 2 Cardiac measures |
|--------------------------|
|                         |
| **Patient 1**           |
| Before | After OLT |
| NYHA-class | II | I |
| AF   | Yes³ | Yes³ |
| Peripheral edema | Yes | No |
| **Patient 2**           |
| Before | After BVZ |
| NYHA-class | III | I |
| AF   | No | No |
| Peripheral edema | Yes | Reduced |
| **Patient 3**           |
| Before | After BVZ |
| Peripheral edema | Yes | Reduced |

³ Paroxysmal

OLT orthotopic liver transplantation, BVZ bevacizumab, NYHA New York Heart Association, AF atrial fibrillation
was not considered an option, due to very severe disease, advanced age and HOCF. The patient subsequently received bevacizumab treatment.

After 18 weeks treatment, CI was reduced from 5.4 to 4.4 L/min/m² (Table 5). NYHA-class had improved from II to I and diuretic treatment was reduced due to alleviation of peripheral edemas. Furthermore, during bevacizumab treatment gastrointestinal bleedings were reduced and the need for blood transfusions ceased (Tables 2, 3). She still did not experience epistaxis (Table 1). At 9 months follow-up she was feeling well and did not experience noteworthy side effects from bevacizumab, compared to the remarkable symptom relief she experienced. The only side effects reported by Patient 2 were vulnerable and flossy nails (Table 4).

Patient 3 was a 66-year-old woman who was initially suspected to have liver cirrhosis. Following referral to the HHT-Centre, she was diagnosed with HHT and found to have liver AVMs and HOCF, with a CI of 5.3 L/min/m² and symptoms of dyspnea, NYHA class III and AF, fatigue, anemia, ascites and peripheral edemas. She had heavy and prolonged epistaxis, also during the night, which was thought to be the cause of her anemia. Despite anemia she was treated with DOAC. The diagnosis of liver cirrhosis was rejected (Tables 1, 2, 3, 4). OLT was not considered an option due to very severe HOCF and pulmonary hypertension. She therefore received bevacizumab treatment.

Following 18 weeks of treatment, CI was reduced from 5.3 to 4.3 L/min/m², NYHA-class improved from III to I. Her ascites had disappeared while her peripheral edemas alleviated and, hence, diuretic treatment was markedly reduced. Hemoglobin levels normalized (Tables 2, 3, 4, 5) and she no longer experienced epistaxis (Table 1). At 9 months follow-up she was feeling well. Patient 3 reported side effects in the form of itchy, dry skin and alopecia areata—a condition she had also suffered from before bevacizumab treatment (Table 4). The bevacizumab-related symptoms were considered insignificant by the patient compared to the remarkable symptom-relief she experienced.

### Table 3 Liver measures

| Patient | Before OLT | After OLT | Before BVZ | After BVZ |
|---------|------------|-----------|------------|-----------|
| Ascites | No         | No        | Yes        | No        |
| Hepatic artery<sup>a</sup> (mm) | 12.6 | – | 11.5 | 11.5 |
| Superior Mesenteric artery<sup>b</sup> (mm) | 6.5 | – | 6.5 | 6.5 |
| Portal vein<sup>c</sup> (mm) | 8.5 | – | 17 | 22 |
| Hepatic vein<sup>d</sup> | 22.3 | – | 15 | 15 |
| Hepatobiliary ischemia | Yes | No | No | No |
| Diuretic treatment | Yes | No | Yes | Reduced |
| Transfusion | No | No | Yes | No |

---

<sup>a</sup> Measured 10–20 mm from coeliac truncus  
<sup>b</sup> Measured 5 mm downstream from the branching off from the aorta  
<sup>c</sup> Measured at the crossing of the hepatic artery  
<sup>d</sup> Measured 5 mm from the inferior vena cava  

OLT orthotopic liver transplantation, BVZ bevacizumab

### Table 4 Biochemistry before and after treatment

| Patient | Before OLT | After OLT | 9-months | Before BVZ | After BVZ | 9-months |
|---------|------------|-----------|----------|------------|-----------|----------|
| Hemoglobin (g/L) | 127.3 | 104.7 | 101.5 | 72.5 | 114.4 | 104.7 |
| ALAT (U/L) | 18 | 121 | 44 | 18 | 23 | 21 |
| ALP (U/L) | 89 | 215 | 232 | 112 | 117 | 100 |
| Bilirubin (mg/dL) | 0.58 | 1.05 | 0.7 | 0.88 | – | – |
| INR | 1.2 | 1.0 | – | 1.4 | – | – |
| Bevacizumab side effects | No bevacizum | Vulnerable and flossy nails | Dry, itchy skin, alopecia |

---

OLT orthotopic liver transplantation, BVZ bevacizumab, ALAT alanine aminotransferase, ALP alkaline phosphatase, INR international normalized ratio
In the current case series of three patients, OLT and treatment with bevacizumab both effectively reduced symptoms caused by liver AVMs. OLT in HHT patients with liver AVMs has previously been the treatment of choice in patients with severe symptoms despite serious adverse effects and complications [36–41]. However, limitations may be the age of the patient, comorbidity or severe right heart failure due to longstanding disease. If patients are excluded from OLT or waiting for OLT, bevacizumab treatment may be considered.

After OLT the liver AVMs are considered cured. However, the patients require life-long immunosuppressive treatment to reduce the risk of organ rejection [42]. One-year mortality following all-cause OLT is between 15–20% and post-transplantation life expectancy is significantly lower than in age-matched controls [43–45]. Additionally, OLT does not reduce the risk of bleeding from the gastrointestinal tract or the nasal mucosa, in contrast to findings during treatment with bevacizumab treatment [31].

Short-term effects of bevacizumab in HHT patients with liver AVMs, as presented in this case series have previously shown very promising results [29–31]. When focusing on the advantages of bevacizumab over OLT, treatment with bevacizumab exerts significantly less physical trauma to the patient as it is administered as an intravenous treatment with a low risk of inducing potentially fatal adverse effects [31, 46].

Thus, bevacizumab may be a significant and clinically relevant treatment option for patients with HHT with liver AVMs, although the liver AVMs are not cured with bevacizumab treatment, and long-term treatment might be necessary. Thus, bevacizumab may be a supplementary treatment option in patients before or in order to postpone or avoid OLT. Timing of OLT in HHT-patients with with liver AVMs and organ dysfunction is crucial. Pulmonary hypertension is a relative contraindication for

### Table 5 Cardiac data—before and after treatment

| Patient 1 | Patient 2 | Patient 3 |
|-----------|-----------|-----------|
| Baseline  | After OLT | Baseline  | After BVZ | Baseline  | After BVZ |
| **ECG**   |           |           |           |           |           |
| Rhythm    | AFLI      | AFLI      | SR        | SR        | AFLI      | AFLI      |
| Heart rate (bpm) | 77 | 90 | 95 | 83 | 86 | 74 |
| **Echocardiogram** | | | | | | |
| LV size   | Normal    | Normal    | Normal    | Normal    | Normal    | Normal    |
| LVEF (%)  | 60        | 50        | 60        | 60        | 60        | 60        |
| Left heart valve disease | No | No | No | No | No | No |
| RV size   | Normal    | Normal    | Slight dilatation | Slight dilatation | Moderate dilatation | Moderate dilatation |
| TAPSE (mm) | 34 | 14 | 31 | 24 | 17 | 20 |
| TR size   | Mild      | Mild      | Moderate  | Moderate  | Moderate  | Moderate  |
| TRG (mmHg) | 43 | 30 | 36 | 41 | 65 | 39 |
| **RHC**   |           |           |           |           |           |           |
| PCWP (mmHg) | 18 | NA | 18 | 21 | 22 | 14 |
| PAP, systolic (mmHg) | 43 | NA | 52 | 60 | 78 | 51 |
| PAP, diastolic (mmHg) | 23 | NA | 21 | 21 | 32 | 22 |
| PAP, mean (mmHg) | 32 | NA | 38 | 40 | 48 | 32 |
| RVp, systolic (mmHg) | 42 | NA | 48 | 60 | 78 | 51 |
| RVp, diastolic (mmHg) | 10 | NA | 11 | 15 | 20 | 9 |
| RAP (mmHg) | 13 | NA | 12 | 12 | 18 | 9 |
| Cardiac output (l/min) | 10.2 | 6.5* | 8.5 | 6.2 | 7.8 | 6.4 |
| Cardiac index (l/min/m²) | 6.6 | 4.5* | 5.4 | 4.4 | 5.3 | 4.3 |
| SVO₂ (%) | 90        | NA        | 86        | 81        | 77        | 85        |
| PVR (WU) | 1.4       | NA        | 2.4       | 2.3       | 3.7       | 2.8       |

* Perioperative

OLT orthotopic liver transplantation, BVZ bevacizumab, AFLI atrial fibrillation, SR sinus rhythm, bpm beats per minute, LV left ventricular, LVEF left ventricular ejection fraction, RV right ventricular, TAPSE tricuspid annular plane systolic excursion, TR tricuspid valve regurgitation, TRG max tricuspid regurgitation gradient, RHC right heart catheterization, PCWP pulmonary wedge pressure, NA not available, PAP pulmonary arterial pressure, RVP right ventricular pressure, RA right atrium pressure, SVO₂ pulmonic arterial oxygen saturation, PVR pulmonary vascular resistance, WU wood units
OLT, and listing must be considered prior to this complication. When that is said, it is difficult to know whether there is a reversibility of both right heart failure and pulmonary hypertension, which leaves it difficult to decide, when the window closes for transplantation. Finally, due to the limited data available from bevacizumab treatment of non-cancer diseases, and specifically HHT, very little is known about adverse effects during long-term treatment. Continuous VEGF-inhibition could markedly affect normal physiological processes such as wound healing, vascular homeostasis and cardiovascular function [24, 47–51]. Furthermore, positive short-term effects, even immensely promising ones, are no guarantee of positive long-term effects.

Conclusion
Identification of symptomatic liver AVMs in patients with HHT is important as they may result in significant clinical symptoms. Until now, OLT has been the mainstay in treatment and OLT leads to satisfying short- and long-term results in patients with HHT and liver AVMs. However, OLT potentially entails serious and in the worst-case life-threatening complications and adverse effects. Yet, treatment options for liver AVMs in patients with severe HHT are currently very limited, and there is no data on long-term effect. Thus, bevacizumab could, as suggested in this case series be a treatment option for patients with symptoms of HOCEF. In some cases this may postpone or could even avoid the need to perform OLT. Bevacizumab represents a promising new treatment option, which should be investigated further in randomized clinical trials.

Abbreviations
ACVR1: Activin receptor-like kinase 1; AF: Atrial fibrillation; AVM: Arteriovenous malformations; CI: Cardiac index; CT: Computed tomography; DOAC: Direct-acting oral anticoagulants; ENG: Endoglin; GI: Gastrointestinal; HHT: Hereditary hemorrhagic telangiectasia; HOCEF: High output cardiac failure; OLT: Orthotopic liver transplantation; TGFβ: Transforming growth factor beta; NYHA: New York Heart Association; VEGF: Vascular endothelial growth factor inhibitor.

Acknowledgements
Not Applicable.

Authors’ contributions
All authors have contributed to the collection of data. LO has drafted the manuscript. All authors have read and approved of the final version.

Funding
The authors have not received funding regarding this manuscript. This refers to all the processes including the design of the study, collection of data, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
All data are available upon request from the corresponding author.

Ethics approval and consent to participate
All participant has consented to participate and this adheres to the local ethics regulations.

Consent for publication
Written informed consent was obtained from all patients, allowing their disease history and CT scans to be published. The signed consents are available upon request.

Competing interests
There are no conflicts or competing interests.

Author details
1. HHT-Center Odense University Hospital, Part of VASCERN, Odense, Denmark.
2. Department of Otoro-hiarynology Head and Neck Surgery, Odense, Denmark.
3. Department of Cardiology, Odense University Hospital, Odense, Denmark.
4. Department of Medical Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.
5. Institute of Clinical Research, Odense, Denmark.

Received: 9 June 2020 Accepted: 13 October 2020

Published online: 26 November 2020

References
1. Sabba C, Pasculli G, Suppressa F, D’Ovidio F, Lenato GM, Resta F, et al. Life expectancy in patients with hereditary haemorrhagic telangiectasia. QJM. 2006;99(5):327–34.
2. Droege F, Thangavelu K, Stuck BA, Stang A, Lang S, Geisthoff U. Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. Vasc Med. 2018;23(4):377–83.
3. Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999;245(1):31–9.
4. Sabba C, Pomplii M. Review article: the hepatic manifestations of hereditary haemorrhagic telangiectasia. Aliment Pharmacol Ther. 2008;28(5):S23–33.
5. Buscarini E, Leandro G, Conte D, Danesino C, Daina E, Manfredi G, et al. Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic telangiectasia. Dig Dis Sci. 2011;56(7):2166–78.
6. Buscarini E, Danesino C, Olivieri C, Lupinacci G, De Grazi F, Reduzzi L, et al. Doppler ultrasonographic grading of hepatic vascular malformations in hereditary hemorrhagic telangiectasia—results of extensive screening. Ultraschall Med. 2004;25(5):348–55.
7. Kjeldsen AD, Moller TR, Bruggaard K, Vase P, Andersen PE. Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia. J Intern Med. 2005;258(4):349–55.
8. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westerman CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia—Rendu–Osler–Weber syndrome. Am J Med Genet. 2000;91(1):66–7.
9. Tonning PM, Bruggaard K, Ousager LB, Andersen PE, Kjeldsen AD. National mutation study among Danish patients with hereditary haemorrhagic telangiectasia. Clin Genet. 2014;86(2):123–33.
10. Karlsson T, Cheri H. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler’s Disease, Uppsala University Hospital. Ups J Med Sci. 2018;123(3):153–7.
11. Jelsig AM, Torning PM, Kjeldsen AD, Qvist N, Bojesen A, Jensen UB, et al. JP-HHT phenotype in Danish patients with SMAD4 mutations. Clin Genet. 2016;90(1):55–62.
12. Cunha SI, Magnusson Pj, Dejana E, Lampugnani MG. Deregulated TGF-beta/Smad signaling in vascular malformations. Circ Res. 2017;121(8):981–99.
13. Gordon KJ, Blome GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782(4):197–228.
14. Pauclu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32(3):291–7.
15. Aa OS, Friedman CM, White RJ Jr. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 1991;101(9):977–80.
16. Dupuis-Girod S, Cottin V, Shovlin CL. The lung in hereditary hemorrhagic telangiectasia. Respiration. 2017;94(4):315–30.
17. Cottin V, Dupuis-Girod S, Lesca G, Corder JF. Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler disease). Respiration. 2007;74(4):361–78.
18. Kjeldsen AD, Oshiro H, Andersen PE, Green A, Vase P. Prevalence of pulmonary arteriovenous malformations (PAVMs) and occurrence of neurological symptoms in patients with hereditary hemorrhagic telangiectasia (HHT). J Intern Med. 2000;248(3):255–62.
19. Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2000;95(2):415–8.
20. Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2000;343(13):931–6.
21. Felli E, Addo P, Faitot F, Nappo G, Onciociu C, Bachelier P. Liver transplantation for hereditary hemorrhagic telangiectasia: a systematic review. HPB (Oxford). 2017;19(7):567–72.
22. Lerut J, Orlando G, Adam R, Sabha C, Pfirrmann R, Klemmepauer J, et al. Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. Ann Surg. 2006;244(6):854–62 (discussion 62–4).
23. Dupuis-Girod S, Chesnais AL, Ginon I, Dumortier J, Saurin JC, Finet G, et al. Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study. Liver Transpl. 2000;6(16):340–7.
24. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12(3):356–61.
25. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713–8.
26. Sin V, Cassano A, Corsi D, De Laurentiis M, Gamucci T, Mauri M, et al. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons. Tumori. 2009;95(2):472–80.
27. Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, et al. Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc. 2010;42(8):2970–2.
28. Enderby C, Keller CA. An overview of immunosuppression in solid organ transplantation. Am J Manag Care. 2015;21(1 Suppl):s12-23.
29. Pareja E, Cortes M, Navarro R, Sanjuan F, Lopez R, Mir J. Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc. 2010;42(8):2970–2.
30. Adam R, Karman V, Delvart V, O’Grady J, Mirza D, Klemmepauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57(3):675–88.
31. Adam R, Karman V, Calliez V, O’Grady JG, Mirza D, Cherqui D, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293–317.
32. Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):28.
33. Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60.
34. Buscarini E, Marfedi G, Zambelli A. Bevacizumab to treat complicated vascular malformations after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc. 2010;42(8):2970–2.
35. Razonable RR, Findlay JY, Rorick KD, Burroughs SG, Ghobrial RM, Agarwal B, et al. Critical care issues in patients after liver transplantation. Liver Transpl. 2011;17(5):511–27.
36. Snijder RJ, et al. Reproducibility of right-to-left shunt quantification using transthoracic contrast echocardiography in hereditary haemorrhagic telangiectasia. Neth Heart J. 2018;26(4):203–9.
37. Vorselaars WM, Velthuis S, Huijtema MP, Hosman AE, Westermann CJ, Snijder RJ, et al. Reproducibility of right-to-left shunt quantification using transthoracic contrast echocardiography in hereditary haemorrhagic telangiectasia. Neth Heart J. 2018;26(4):203–9.
38. Faenza S, Santoro A, Mancini E, Pareschi S, Siniscalchi A, Zanzani C, et al. Acute renal failure requiring renal replacement therapy after orthotopic liver transplantation. Transplant Proc. 2006;38(4):1141–2.
39. Liu T, Zhang Y, Wan Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients. Infect Drug Resist. 2018;11:2345–56.
40. Pisano F, Fracanzani AL, Caccamo L, Donato MF, Fargion S. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol. 2016;22(40):8869–82.
41. Porcelli F, Carollo C, Barbieri S, Pettenazzo T, Ori C. Early respiratory complications after liver transplantation. World J Gastroenterol. 2013;19(46):9271–81.
42. Razonable RR, Findlay JY, O’Riordan A, Burroughs SG, Ghobrial RM, Agarwal B, et al. Critical care issues in patients after liver transplantation. Liver Transpl. 2011;17(5):511–27.
43. Aberg F, Gissler M, Karlsten TH, Ericzon BG, Foss A, Rasmussen A, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 2015;61(2):668–77.
44. Razonable RR, Findlay JY, Rorick KD, Burroughs SG, Ghobrial RM, Agarwal B, et al. Critical care issues in patients after liver transplantation. Liver Transpl. 2011;17(5):511–27.
45. Adam R, Karman V, Delvart V, O’Grady J, Mirza D, Klemmepauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57(3):675–88.
46. Adam R, Karman V, Gailliez V, O’Grady JG, Mirza D, Cherqui D, et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293–317.
47. Buscarini E, Botella LM, Geisthoff U, Kjeldsen AD, Mager HJ, Pagella F, et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019;14(1):28.
48. Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60.
49. Qureshi S, Elliott RB, Herrington JD. Concurrent gastrointestinal perforation and pulmonary embolism due to bevacizumab in an adult undergoing treatment for stage IV colon cancer. J Oncol Pract. 2017;23(8):625–8.
50. Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016;7(50):82473–81.
51. Gressett SM, Shah SR. Intracranial bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490–501.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.